Can-Fite BioPharma (CANF) Common Equity (2013 - 2025)
Can-Fite BioPharma's (CANF) quarterly Common Equity came in at $5.6 million in Q4 2025, up 2.87% YoY from $5.4 million in Q4 2024, and up 33.65% on a QoQ basis from $4.2 million in Q2 2025.
Can-Fite BioPharma (CANF) Common Equity (2013 - 2025) Analysis & Trends
Can-Fite BioPharma (CANF) has 13 years of Common Equity data on file, last reported at $5.6 million in Q4 2025.
- Quarterly Common Equity rose 2.87% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.6 million (up 2.87% YoY) and the FY2025 annual result came in at $5.6 million, up 2.87% from the prior year.
- Common Equity rose to $5.6 million in Q4 2025, from $4.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $14.4 million in Q4 2021 to a low of $2.5 million in Q2 2024.
- A 5-year average of $7.1 million and a median of $6.6 million in 2023 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 150.11% in 2022, down 68.91% in 2022.
- Tracing CANF's Common Equity over 5 years: stood at $14.4 million in 2021, then sank by 68.91% to $4.5 million in 2022, then jumped by 39.6% to $6.2 million in 2023, then retreated by 12.93% to $5.4 million in 2024, then climbed by 2.87% to $5.6 million in 2025.
- The last three Common Equity figures came in at $5.6 million (Q4 2025), $4.2 million (Q2 2025), and $5.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 9.79 Bn |
| 10 | Can-Fite BioPharma | 2.78 Mn | -8.77 Mn | - | 5.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.59 Mn |
| Jun 30, 2025 | 4.18 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Jun 30, 2024 | 2.48 Mn |
| Dec 31, 2023 | 6.24 Mn |
| Sep 30, 2023 | 5.24 Mn |
| Jun 30, 2023 | 6.87 Mn |
| Mar 31, 2023 | 8.49 Mn |
| Dec 31, 2022 | 4.47 Mn |
| Sep 30, 2022 | 7.43 Mn |
| Jun 30, 2022 | 9.89 Mn |
| Mar 31, 2022 | 12.02 Mn |
| Dec 31, 2021 | 14.38 Mn |
| Sep 30, 2021 | 9.33 Mn |
| Jun 30, 2021 | 3.96 Mn |
| Mar 31, 2021 | 7.08 Mn |
| Dec 31, 2020 | 6.07 Mn |
| Jun 30, 2020 | 9.16 Mn |
| Dec 31, 2019 | 2.44 Mn |
| Sep 30, 2019 | 7.06 Mn |